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Veterinary vaccinology is a very interesting and rapidly developing field. In fact veterinary 
vaccines are not only used for the prevention of infectious diseases in the animal health sector, 
but also help to solve problems of public health, to reduce detrimental environmental impact of 
the use of some veterinary drugs and prevent the emergence of resistance of micro-organisms or 
parasites. After a short introduction, this paper will deal with the use of vaccines for animal 
health and welfare, including new developments in the veterinary field such as marker vaccines 
and vectored vaccines, the special case of equine influenza-inactivated vaccines and the use of 
veterinary vaccines in public health. The conclusions will analyze the reasons as to why develop 
veterinary vaccines and the obstacles to their development. © 1999 Académie des sciences/ 
Editions scientifiques et médicales Elsevier SAS 
RÉSUMÉ 
La vaccinologie vétérinaire est un secteur en plein développement et d'un profond intérêt. Les 
vaccins vétérinaires ne sont pas seulement utilisés pour préµevenir (rarement traiter) les 
maladies infectieuses des animaux mais également dans beaucoup d'autres domaines comme 
celui de la santé publique et pour diminuer les conséquences néfastes pour l'environnement qui 
peuvent résulter de l'emploi de certains médicaments vétérinaires. Enfin, l'utilisation de certains 
vaccins permet de pallier l’émergence de résistances bactériennes ou parasitaires a certains de 
ces médicaments. Après une brève introduction qui définit le marché du vaccin vétérinaire et les 
différences qui peuvent exister entre le marché des différentes espèces animales domestiques, 
cette contribution se propose de décrire les principales nouveautés dans le secteur, comme celle 
des vaccins marqués et des vaccins vectorisés dans le cadre de la santé et du bien-être animal. Le 
cas particulier des vaccins inactivés destinés a prévenir la grippe équine sera par la suite évoqué 
ainsi que la répercussion des vaccins vétérinaires en santé publique. Les conclusions seront 
consacrées a une analyse des raisons en faveur du développement des vaccins vétérinaires ainsi 
que celles qui font obstacle a pareil développement. 
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Veterinary vaccinology is a newly defined scientific discipline. The reasons for considering 
veterinary vaccinology as a new scientific discipline are many fold:  
- the approach of vaccinology is multidisciplinary including immunology, epidemiology, 
microbiology, virology, parasitology, reproductive physiology, veterinary clinical sciences, etc.; 
- veterinary vaccinology covers a broad scope of objectives; molecular biology has had a strong 
impact on veterinary vaccinology, bringing new insights and broadening the perspectives; 
- the market for veterinary vaccines differs markedly from the human one. 
Moreover, veterinary vaccinology often provides the opportunity to test new developments in 
the field of vaccinology. When defining the goal for a vaccine one must nowadays consider the 
impact of the vaccine, either simply the prevention or the reduction of the clinical signs 
associated with an infection for instance, or the prevention or reduction of the infection itself in 
order to hamper the spreading of infectious agents (epidemiological purposes). 
Veterinary vaccines are not only used in the animal health sector itself but also for other 
purposes such as improvement of public health, reduction of environmental impact of other 
veterinary drugs, improvement of animal welfare, control of animal pests, etc. 
This contribution will try to give an overview of the present developments and future trends in 
veterinary vaccinology. 
One must always keep in mind that in the veterinary field there are two major categories of 
species: food producing ones considered basically as economic goods such as cattle, pigs and 
poultry, and pets such as dogs, cats and horses. The market of veterinary vaccines will be 
strongly influenced accordingly. 
The market of veterinary vaccine 
The world market for veterinary vaccines was estimated in 1993 to be at 1.8 million US dollars 
gross [1] and consists of about 20% of the market for all animal health products; this represents 
approximately 5% of the value of the pharmaceutical (human and veterinary use) market. The 
size of the veterinary vaccine market is equivalent to the size of the market for human vaccines 
[2]. However, the market for veterinary vaccines covers the existence of approximately 160 
different vaccinal agents as compared to approximately 30 for human use. The number of 
vaccines is therefore higher, resulting in a much lower turn-over per product. To conclude, the 
role of veterinary vaccines within veterinary medicinal products is very important, but 
veterinary vaccines suffer from several drawbacks: 
- the markets are often small; 
- the markets are heterogeneous between different countries especially for food-producing 
animals; 
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- those products are highly specific; many species are potential targets; 
- many different conditions are involved. 
Nevertheless one must always keep in mind that in the absence of broad spectrum antivirals, 
vaccination is often the only means of preventing or curing viral infections 
Marker vaccines used for epidemiological purposes 
In veterinary medicine, sanitary authorities may either choose to vaccinate against a disease as a 
method of prevention or decide to eliminate the infection using slaughtering programmes either 
on large scale or on a case by case basis. In some cases such as African swine fever in the 
complete absence of a vaccine, there is still no other choice than to eliminate the infection as 
quickly as possible by slaughtering and destruction of the carcasses. 
On top of that, in the field of veterinary viral vaccines, most of the previous vaccines were only 
developed to prevent clinical signs of the disease without paying too much attention to their 
epidemiological impact on impeding wild virus excretion and spreading after subsequent field 
infection. 
Major changes are nevertheless foreseen owing to changes in public opinion, slaughtering 
policies being less and less popular (animal welfare concern) and the availability of marker 
vaccines. 
Marker vaccines are vaccines that can be used within the framework of an elimination 
programme because they allow us to distinguish between animals that are infected and those 
that are simply vaccinated. Marker vaccines are either obtained by the deletion of a gene coding 
for a non-essential protein of the infectious agent (until now viruses) or are sub-unit vaccines. 
They must always be associated with a companion diagnostic test allowing the distinction 
between infection and vaccination. In the case of a deletion the marker property is always linked 
to the deleted protein; in the case of a sub-unit vaccine several possibilities may exist. 
Nevertheless for harmonisation purposes a choice should be made. The marker is always 
negative since a positive marker such as that linked to the insertion of a gene coding for a 
foreign protein is useless since it will only tell that the animal has been vaccinated but not if it 
has been infected. Marker vaccines have been developed for Aujeszky's disease virus infection of 
the pig (often called pseudorabies) (gE deletion), classical swine fever (pestivirus infection of 
the pig; E2 subunit vaccine) and infectious bovine rhinotracheitis (herpesvirus infection of 
cattle; gE deletion or gD subunit). One of the best example is infectious bovine rhinotracheitis 
(IBR) caused by bovine herpesvirus 1 [3]. Previous IBR vaccines were mainly developed to 
prevent clinical consequences of wild virus infection. Infectious bovine rhinotracheitis be- longs 
to the list B of the Office international des epizooties and this infection can therefore impede 
international trades if it is implemented in some national elimination programmes. In western 
Europe most countries have chosen or are forced to implement a programme of infectious 
bovine rhinotracheitis elimination. Infectious bovine rhinotracheitis virus, like other 
herpesviruses, remains latent after infection. Unfortunately, the wild virus can establish latency 
in already vaccinated animals either with an inactivated vaccine or with an attenuated one. 
Conversely an animal remains a latent carrier of a wild virus if it is vaccinated after field 
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infection. Moreover, so far all the attenuated strains of infectious bovine rhinotracheitis virus 
remain latent after vaccination, even the gE deleted ones and can be reactivated later on [4]. 
Therefore, in areas where cattle are vaccinated with either an inactivated or an attenuated 
conventional vaccine, one cannot distinguish between animals either vaccinated or infected, 
whilst in areas where vaccination is non-authorised, all animals that are seropositive against IBR 
virus must be considered as infected. If an elimination programme is implemented in a 
vaccination area, all seropositive animals, either vaccinated or infected, must be eliminated from 
the herds. As a matter of fact, in a vaccinated area, a serologically positive animal may be either: 
- vaccinated; 
- infected; 
- vaccinated and infected; 
- infected and vaccinated. 
Unfortunately due to vaccination programmes against clinical disease, some western European 
countries show a high prevalence of seropositive animals (60-70%). 
This has led to the use of marker vaccines. The protein chosen as a marker must show several 
characteristics: 
- be non-essential (in order to be able to produce the vaccine); 
- not be a major immunogen (in order to maintain vaccine efficacy); 
- give a long living serological response when present (to be a marker); 
- be present in all the wild strains so far studied; 
- induce a serological response in already vaccinated animals. 
In this case, whenever an animal is seropositive against the deleted protein, even after 
vaccination, it is infected and must be eliminated. 
Vectored vaccines 
Vectored vaccines are vaccines consisting of an attenuated infectious agent able to multiply in 
the target animal and harbouring foreign gene(s) of interest. The vector itself may be an 
immunogenic component of the vaccine. 
Some of the vector may be 'suicide' vectors; that is to say that they only undergo one 
multiplication cycle in the target host without producing progeny. 
The best example of this kind of vaccine in the veterinary field is the use of a vaccinia-rabies 
recombinant vaccine for the control and elimination of wildlife rabies [5]. 
The recombinant vaccinia-rabies glycoprotein virus (VRG) has been tested for efficacy and 
safety in the fox [6, 7]. The duration of protection conferred by VRG, a minimum of 12 months in 
cubs and 18 months in adult animals, corresponds to the length of protection required for fox 
vaccination in the field owing to the high turnover of the fox population. The efficacy of VRG 
contained in a machine-made baiting system has been tested and shown to be effective. 
VRG was shown to be non-pathogenic in the fox what- ever the inoculation dose or route of 
administration. No transmission of immunising amounts of VRG was found to occur in adults or 
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young foxes, with the exception of one adult fox bitten by another freshly vaccinated one. VRG 
only multiplies locally. 
The influence of vaccination with VRG on the onset of the disease and on the delay before death 
in foxes previously infected with wild rabies virus, has been investigated. The results show that 
'early' and 'late' death phenomena occur as a consequence of interactions between oral 
vaccination with VRG and rabies infection, but preclude the risk of the emergence of 
asymptomatic carriers of wild-rabies virus after vaccination. 
Field trials with baits have shown that several non-target wildlife species compete with foxes for 
bait consumption. It must also be taken into account that, within the ortho- poxvirus group, the 
vaccinia virus has a wide range of host species. In fact, bait uptake monitoring and tetracycline 
(biomarker included within the bait) detection controls, performed after vaccination campaigns, 
proved that mustelids, wild boars (Sus scrofa) and domestic carnivores may ingest the vaccine 
baits. Moreover, a significant proportion of the baits are partly eaten by small mammals. It was 
therefore important to verify the safety of VRG for non-target species (both domestic and wild). 
Several non-target wild species have been chosen for testing in Europe because of their 
opportunistic feeding behaviours and their presence in the areas where the vaccine must be 
distributed, including the wild boar, Eurasian badger (Meles meles) and several micromammals. 
No clinical signs of rabies and/or pox infected lesions were observed in the vaccinated animals 
during the observation period (28 days minimum after vaccination). 
Taking into account all the available experimental data concerning the safety of the VRG for 
target and non-target species and its efficacy in foxes, limited field trials of fox vaccination with 
the recombinant virus were authorised first by the Belgian and then by the French public health 
authorities. The last trial of deliberate release of the VRG on a 2 200 km2 area of southern 
Belgium was intended to test the feasibility of rabies elimination on a large area. The 25 000 
baits containing VRG and tetracycline as a bio- marker were dropped by helicopter on three 
occasions (November 1989, April 1990 and October 1990). After the third phase of vaccination, 
81% of inspected foxes were tetracycline positive. Only one rabid fox was recorded, at the 
periphery of the baited area, and this was tetracycline negative. Despite the dramatic decrease in 
the number of rabid foxes recorded after vaccine-bait distribution, the efficacy of the vaccination 
campaign remains difficult to evaluate because systematic collection of foxes is not logistically 
feasible. Nevertheless, because notification of cases of rabies in cattle and sheep is mandatory in 
Belgium, the incidence of rabies in livestock provides a reliable indicator of the prevalence of 
rabies in the wild. No case of livestock rabies has been recorded in the study zone since the 
second phase of vaccination. On this occasion, we have also investigated the economics of the 
vaccine-bait dispersal programme. The average yearly cost of rabies in Belgium (1980--1989), 
including post- exposure treatments of humans, animal diagnosis, compensation to farmers for 
the culling of infected livestock and the culling of wild foxes, was estimated to be 400 000 Euros 
per 10 000 km2, or 88 000 Euros per year for the area under study. These figures did not include 
the cost of vaccination of domestic animals nor the salaries of civil servants. In comparison we 
estimate the overall expenditure during the three campaigns of vaccine-bait distribution to be 
118 000 Euros. Because vaccination following elimination can in principle be interrupted or 
subsequently limited to the borders of the vaccinated zone, long-term maintenance of a rabies-
free area by peripheral vaccination with VRG is economically justifiable [8, 9]. 
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The use of VRG has now been extended to all the contaminated areas in Belgium and the Grand 
Duchy of Luxembourg as well as to large areas in France. Rabies is approaching the stage of 
elimination in these three countries [10). 
The quasi elimination of rabies in Belgium has already had other beneficial effects besides the 
improvement of animal health. First, the number of human post-exposure treatments has 
decreased in proportion to the decrease in rabies incidence in animals (mainly cattle). Second, 
the diminution in rabies incidence in wildlife has had a beneficial effect on the survival of 
threatened wild species, such as the Eurasian badger in the contaminated area. Estimation of the 
badger population in the treated area shows a gradual increase in numbers. 
The same approach (baiting system) has been used in order to control the wild red fox 
population in Australia, where this introduced, non-indigenous species is consid- ered as being a 
pest [11]. 
The case of equine influenza 
Horses are peculiar animals in the sense that they rep- resent the only domestic species 
behaving like man; that is to say free to circulate from one country to another, even from one 
continent to another, without necessarily being quarantined, provided they are duly vaccinated 
against equine influenza 15 d before travel at the latest. Equine influenza belongs to list B of the 
Office international des epizooties. 
Equine influenza has remained among the main acute contagious respiratory diseases of horses 
worldwide. Equine influenza is represented by two subtypes: influenza Nequine 2 virus (H3N8) 
which is the most important cause of respiratory disease in the horse, and influenza Nequine 1 
virus (H7N7) which is still circulating subclinically but is almost considered as extinct. 
However, a divergence in the evolution of Nequine 2 (H3N8) viruses has occurred since 1987 
and two families of virus are now circulating. These were designated European-like and 
American-like, although representatives of both families have been isolated in both continents 
[12]. There is increasing evidence from field studies that antigenic drift in the gene coding for 
haemagglutinin (HA), which is the major surface protein of these influenza A strains, eventually 
renders vaccine strains obsolete and is likely to compromise vaccine efficacy [13, 14]. In fact, the 
more the vaccine strain is related to field viruses, the more the vaccine can protect against field 
virus excretion and circulation, which is the ultimate goal. A formal reporting mechanism on 
antigenic/genetic drift or shift of equine influenza viruses and a vaccine strain selection system 
have been set up, so that vaccine manufacturers and regulatory authorities are informed of the 
potential need to update vaccine virus strains. An expert surveillance panel, including 
representatives from three WHO reference laboratories and from three OIE reference 
laboratories, reviews every year the epidemiological and virological information and make 
recommendations about suitable vaccine strains. These recommendations are published 
annually by the OIE in its bulletin (OIE, 1996). As antigenic drift in equine influenza occurs at a 
slower rate than in human influenza, it is considered that a regular update of the strains could be 
necessary every 3-5 years. What is even more important is the fact that the development of 
effective vaccines can now be facilitated by the availability of reliable in vitro assays such as: 
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- single radial diffusion (SRO) to measure vaccine bulk antigen content in terms of 
haemagglutinin (HA) content; 
- single radial haemolysis (SRH} to measure serological responses. 
For in-process controls, SRD provides a reliable method of measuring haemagglutinin content of 
equine influenza bulk antigens, although it cannot be used on final adjuvanted products [15], 
while SRH is a sensitive and reproducible method for measuring antibody to haemagglutinin. 
Moreover, the European Agency for the Evaluation of Medicinal Products (EMEA) based in 
London has taken the initiative to shorten the procedure of strain replacement in equine 
influenza vaccines when required according to epidemiological circumstances in case of an 
antigenic shift. This will allow us not only to accelerate the procedure but also to reduce the 
number of animals necessary for vaccine development and control in accordance with the three 
Rs rules (reduction, replacement, refinement) [16]. 
New equine influenza antigenic variants to be used in vaccine production could be obtained by 
selection of appropriate reassortants as already carried out for human influenza vaccines. 
Veterinary vaccines and animal health and welfare 
As already mentioned, the public concern for animal welfare is increasing, leading to the 
establishment and implementation of the three Rs rule [ 17]. 
The value of animal models for veterinary vaccines is not to be ignored, particularly since one 
has access to target animal models which are often more relevant than the laboratory ones, 
especially for challenge/protection studies. Immune protection involves complex immunological 
phenomena and processes. It is particularly true whenever cellular immunity plays a crucial role 
because it is still easier to measure antibody responses than cellular ones in vitro. 
Nevertheless the trend is to replace animal models by in vitro systems whenever possible. The 
problem of the replacement of the in vivo model by in vitro ones is further impeded in Europe by 
the necessity to comply with Pharmacopoeia monographs where the use of laboratory and/or 
target animals is often requested. As far as the use of veterinary vaccines itself is concerned the 
benefit for animal welfare is obvious. Vaccines unlike therapeutic treatments are the best way to 
avoid animal suffering since they prevent disease. Furthermore, due to the short life time of 
many categories of food-producing animals, the vaccine must only be administered once in 
contrast to treatments which generally necessitate repeated interventions. Nevertheless, there is 
still room for improvement by developing less reactogenic adjuvanted vaccines. Another area of 
animal health improvement is the use of vaccines for immunocastration of male pigs to avoid 
boar taint, instead of surgical castration. The use of vaccines in animal production systems is 
also often more environment friendly since it reduces the use of chemicals. Of special interest is 
the anti-tick vaccine developed in Australia based on a cryptic intestinal antigen [18]. 
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Veterinary vaccines and public health 
In developed countries, due to overproduction, the public concern for food security has been 
replaced by a major concern for food safety. This concern has overwhelmingly increased after 
the mad cow crisis. People are concerned with food poisoning, the presence of drug residues 
following treatment of food-producing animals and the possible bacterial transfer of resistance 
to antibiotics from animal to man. 
Veterinary vaccines may help to solve many of those problems. The best example of a veterinary 
vaccine used for public health purposes is the vaccination of wildlife against rabies; the primary 
goal is not to protect wildlife species from rabies but indirectly to avoid human exposure and 
contamination as well. 
Being considered as products working by natural mechanisms, vaccines, except for some of their 
excipients, do not need to have an MRL (maximum residue limit) determination associated with 
a withdrawal period. In fact, since vaccine prevention works after a lag period the use of 
vaccines intrinsically contains a withdrawal period. Veterinary vaccines can also be used to 
prevent food poisoning as exemplified by the 'in ovo' [19] vaccination of poultry against 
salmonellosis, in order to decrease carcass contamination. Vaccines against sheep cysticercosis 
have been experimentally developed (20] leading to the possible control of bovine cysticercosis 
in order to prevent Taenia saginata taeniosis in man. 
Last but not least, bacterial resistance to antibiotics is an emerging problem for both animal and 
public health sectors. Several antibacterial vaccines used in veterinary medicine disappeared 
after the second world war, being replaced by antibiotics. The resistance to antibiotics in the 
animal health sector with possible implications (although rarely) for human health as well as the 
resistance of several parasites to anthelmintics may lead to the reappearance or the appearance 
of antibacterial and antiparasitic vaccines. Even if other pathways such as selection of food- 
producing animals for genetic resistance may be followed, the story of Marek's disease in 
chicken shows us that vaccines are often the more economical way to procure an animal's 
resistance to pathogens. 
Conclusions 
In conclusion, one may ask the question as to why we develop veterinary vaccines and where we 
stand? The reasons for developing veterinary vaccines are many fold: 
- to protect animal health; 
- to improve animal welfare; to protect public health; 
- to protect consumers of the products of food- producing animals; 
- to better protect the environment; 
- to avoid the emergence of pathogen resistance to available drugs. 
Even if the reasons for developing veterinary vaccines are many, there are also many obstacles 
to their development: 
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- scientific obstacles (e.g. African swine fever, many anti-parasitic vaccines); 
- poor investment return for the companies involved in this business; 
- the existence of so-called minor species as targets; 
- the existence of conditions of minor importance in so-called 'major' species; 
- the existence of conditions of minor importance in so-called 'minor' species; 
- the existence of interdiction due to animal health regulation; 
- regulatory requirements for vaccines registration. 
Published in : C. R. Acad. Sci. Paris, Sciences de la vie I Life Sciences (1999), vol. 322, no.11, 
pp. 967-972 
DOI: 10.1016/S0764-4469(00)87194-2 





Pastoret P.P., Blancou J., Vannier P., Verschueren C. (Eds.), Veterinary Vaccinology, Elsevier Science, 
Amsterdam, 1997. 
Pastoret P.P., Griebel P., Bazin H., Govaerts A., Handbook of Vertebrate Immunology, Academic Press, San 
Diego, 1998. 
Wood P.R., Willadsen P., Vercoe J.E., Hoskinson R.M., Demeyer D., Vaccines in Agriculture, Immunological 
Applications to Animal Health and Production, CSIRO, Australia, 1994. 
Manual of Standards for Diagnostic Tests and Vaccines, Office international des epizooties (world 
organisation for animal health), Paris, 1996. 
References 
[1] Zänker S., Leunen J., Verschueren C., The market for veterinary vaccines and future perspectives, in: 
Pastoret P.P., Blancou J., Vannier P., Verschueren C. (Eds.), Veterinary Vaccinology, Elsevier Science, 
Amsterdam, 1997, pp. 736-740. 
[2] EFPIA, Study on vaccines for human use and their rational use in Europe and worldwide, EFPIA, 
Brussels, 1993. 
[3] Pastoret P.P., Thiry E., Brochier B., Derboven G., Vindevogel H., The role of Iatency in the epizootiology 
of infectious bovine rhinotracheitis, in: Wittmann A., Gaskell R., Rziha H.J. (Eds.), Latent Herpesvirus 
Infections in Veterinary Medicine, Martinus Nijhoff Pub., 1984, pp. 211-22. 
[4] Pastoret P.P., Babiuk L.A., Misra V., Griebel P., Reactivation of temperature sensitive and non-
temperature sensitive infectious bovine rhinotracheitis vaccine virus with dexamethasone, Infect. lmmun. 
29 (1980) 483-488. 
[5] Pastoret P.P., Brochier B., Bfancou LArtois M., Aubert M., Kieny M.P., Lecocq J.P., Languet B., Chappuis 
G., Desmettre P., Development and deliberate release of a vaccinia-rabies recombinant virus for the oral 
vaccination of foxes against rabies, in: Binns M.M., Smith G.L. (Eds.), Recombinant Poxviruses, CRC Press, 
Boca Raton, 1992, pp. 163-206. 
[6] Kieny M.P., Lathe R., Drillien R., Spehner D., Sory S., Schmitt D., Wiktor T., Koprowski H., Lecocq J.P., 
Expression of rabies virus glycoprotein from a recombinant vaccinia-virus, Nature 312 (1984) 163-166. 
[7] Blancou J., Kieny M.P., Lathe R., Lecocq J.P., Pastoret P.P., Soulebot J.P., Desmettre P., Oral vaccination of 
the fox against rabies using a live recombinant virus, Nature 322 (1986) 373-375. 
[8] Pastoret P.P., Brochier B., Languet B., Thomas I., Paquot A., Bauduin B., Costy F., Antoine H., Kieny M.P., 
Lecocq J.P., Debruyn J., Desmettre P., First field trial of fox vaccination against rabies with a vaccinia-rabies 
recombinant virus, Vet. Rec. 123 (1988) 481-483. 
[9] Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., Languet B., Chappuis G., Desmettre 
P., Afiademanyo K., Libois R., Pastoret P.P., Large-scale eradication of rabies using recombinant 
vaccinia-rabies vaccine, Nature 354 (1991) 520-522. 
[10] Pastoret P.P., Brochier B., Epidemiology and elimination of rabies in Western Europe, Vet. J. 156 
(1998) 83-90. 
Published in : C. R. Acad. Sci. Paris, Sciences de la vie I Life Sciences (1999), vol. 322, no.11, 
pp. 967-972 
DOI: 10.1016/S0764-4469(00)87194-2 




[11] Tyndale-Biscoe H., Bradley M., Vaccination for wildlife contraception, in: Pastoret P.P., Blancou J., 
Vannier P., Verschueren C. (Eds.), Veterinary Vaccinology, Elsevier, Amsterdam, 1997, pp. 492-498. 
[12] Daly J.M., Lai A.CK., Binns M.M., Chambers T.M., Barrandeguy M., Mumford J.A., Recent worldwide 
antigenic and genetic evolution of equine H3N8 influenza A viruses, J. Gen. Virol. 77 (1995) 661-671. 
[13] Mumford J.A., Chambers T., Wood J., Consultation of OIE and WHO experts on progress in surveillance 
of Equine influenza and application to vaccine strain selection, OIE 64th General Session, Standards 
Commission Report, 1996. 
[14] Mumford J.A., Wood J., Conference report in WHO/OIE meeting: consultation of emerging strains of 
equine influenza, Vaccine 11 (1993) 1172-1175. 
[15] Wood J.M., Schild G.C., Folkers C., Mumford J., Newman R.W., The standardisation of inactivated 
influenza vaccines by single-radial immunodiffusion, J. Biol. Standard. 11 (1983) 133-136. 
[16] Weisser K., Hechler U., Animal welfare aspects in the quality control of immunologicals. A critical 
evaluation of the animal tests in Pharmacopoeial monographs, Paul-Ehrlich lnstitut (PEI), Bundesamt für 
Sera und lmpfstoffe, ECVAM and PEI, 1997. 
[17] Morton D.B., Ethical and refinement aspects of animal experimentation, in: Pastoret P.P., Blancou J., 
Vannier P., Verschueren C. (Eds.), Veterinary Vaccinology, Elsevier Science, Amsterdam, 1997, pp. 763-
785. 
[18] Tellam R.L., Wright I., Johnson K.S., (Anti)-parasitic vaccines, in: Pastoret P.P., Blancou J., Vannier P., 
Verschueren C. (Eds.), Veterinary Vaccinology, Elsevier Science, Amsterdam, 1997, pp. 470-489. 
[19] Sharma J.M., Burmeister B., Resistance to Marek's disease at hatching in chickens vaccinated as 
embryos with the tarkey herpesvirus, Avian Dis. 26 (1982) 134-149. 
[20] Johnson K.S., Harrison G.B.L., Lightowlers M.W., O'Hoy K.L., Cougfe W.G., Dempster R.P., Lawrence S.B., 
Vinton J.G., Heath D.D., Richard M.D., Vaccination against ovine cysticercosis using a defined recombinant 
antigen, Nature 338 (1989) 585-587. 
